In the European Union,<unk>  is indicated for the treatment of achondroplasia in people two years of age and older whose epiphyses are not closed. In the United States,<unk>  is indicated to increase growth in children five years of age and older with achondroplasia and open epiphyses (growth plates).
Vosoritide
Oprelvekin
Selexipag
Eteplirsen
Ganirelix
Tezacaftor
Ecallantide
Vagisil